Back to Results

EFTA00489771.pdf

Source: DOJ_DS9  •  Size: 101.7 KB  •  OCR Confidence: 85.0%
PDF Source (No Download)

Extracted Text (OCR)

From: To: Rich Kahn Subject: Re: Date: Thu, 17 Jan 2019 22:20:51 +0000 got it! thanks On Jan 17, 2019, at 5:20 PM, Richard Kahn wrote: i asked JEE and he said to ignore so no need to follow up with jee.. thanks Richard Kahn MO= tel fax cell On Jan 17, 2019, at 4:04 PM, wrote: Thx Sent from my iPhone On Jan 17, 2019, at 3:50 PM, Richard Kahn wrote: i will mention to jee when we speak next thanks Richard Kahn cell fax tel EFTA00489771 On Jan 17, 2019, at 12:19 PM, Christina requested I forward you the below `catch up' email. BioHebe cell: CIllail: \IA vi.biohthe.com <1506365439123b1ob.jpg> Forwarded Message Fro To: < >: Sent: Wednesday, January 16, 2019. 11:22:06 PM EST Subject: Catching Up Dear Jeffrey > > wrote: I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I might use the foundation's Lexington office conference room from time to time for my work and what I could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email? Since working for your foundation, I continued to publish as a journalist writing mostly about genetic vectors (Newsweek, Teclzonomy etc). I then set up an LLC that provides business development for labs that have reversed age-driven or degenerative diseases. Most of the therapies are genetic vectors, and have to show remarkable results at the mouse level and beyond. Regenerative medicine is a rapidly evolving field, and one that forces the medical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US. And I am collaborating with a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver disease in rats using the master transcription gene in hepatocytes. The concept of the latter gene vector is really intriguing in that a master transcription gene completely restored liver function by rebalancing genetic expression and thus proteostasis. While I don't really need an office at this point, I do need access to a conference room from time to time and it would be hugely helpful if I could access the foundation's. If there was some work that I could do for the foundation in exchange, I would be delighted to do that. EFTA00489772 It would be wonderful to catch up with you as well. all the best, BioHebe I.LC: cell: email: - www.Mohehe.com <1506365439123b1ob.jpg> <1506365439123blobjpe<1506365439123blobjpg> EFTA00489773

Document Preview

PDF source document
This document was extracted from a PDF. No image preview is available. The OCR text is shown on the left.

Document Details

Filename EFTA00489771.pdf
File Size 101.7 KB
OCR Confidence 85.0%
Has Readable Text Yes
Text Length 2,772 characters
Indexed 2026-02-11T22:14:38.648717
Ask the Files